OMGA Stock Overview
Operates as a clinical-stage biotechnology company. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Omega Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.83 |
| 52 Week High | US$6.30 |
| 52 Week Low | US$0.75 |
| Beta | 1.68 |
| 1 Month Change | 4.50% |
| 3 Month Change | -36.95% |
| 1 Year Change | -73.15% |
| 3 Year Change | -93.14% |
| 5 Year Change | n/a |
| Change since IPO | -94.80% |
Recent News & Updates
Recent updates
Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'
Mar 31Is Omega Therapeutics (NASDAQ:OMGA) Weighed On By Its Debt Load?
Feb 28
Omega Therapeutics: The Next Weight Loss Drug Runner
Jan 16Omega Therapeutics: Starting 2024 With A Bang
Jan 10Omega Therapeutics GAAP EPS of -$0.54 in-line, revenue of $0.48M beats by $0.43M
Aug 04Omega Therapeutics gets FDA nod to start liver cancer trial of lead drug OTX-2002
Jul 14Shareholder Returns
| OMGA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.4% | -3.3% | -0.4% |
| 1Y | -73.2% | -2.7% | 24.8% |
Return vs Industry: OMGA underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: OMGA underperformed the US Market which returned 24.8% over the past year.
Price Volatility
| OMGA volatility | |
|---|---|
| OMGA Average Weekly Movement | 15.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OMGA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: OMGA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 94 | Kaan Certel | omegatherapeutics.com |
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company’s OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury.
Omega Therapeutics, Inc. Fundamentals Summary
| OMGA fundamental statistics | |
|---|---|
| Market cap | US$46.08m |
| Earnings (TTM) | -US$73.09m |
| Revenue (TTM) | US$8.10m |
5.7x
P/S Ratio-0.6x
P/E RatioIs OMGA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OMGA income statement (TTM) | |
|---|---|
| Revenue | US$8.10m |
| Cost of Revenue | US$42.59m |
| Gross Profit | -US$34.50m |
| Other Expenses | US$38.59m |
| Earnings | -US$73.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.32 |
| Gross Margin | -426.16% |
| Net Profit Margin | -902.93% |
| Debt/Equity Ratio | 135.0% |
How did OMGA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:10 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Omega Therapeutics, Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ryan Deschner | CGS International |
| Keay Nakae | Chardan Capital Markets, LLC |
| Robert Burns | H.C. Wainwright & Co. |